Clinical trial
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65…
NCT00405756 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00405756 |
|---|---|
| Title | A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. |
| Official title | A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (Revlimid®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In Subjects With Newly Diagnosed Multiple… |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Newly Diagnosed Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Lenalidomide: Double-blind Induction, Melphalan, Prednisone, Aspirin, Placebo, Lenalidomide: Double-blind Maintenance, Lenalidomide: Open-label |
| Enrollment | 459 |
| Start date | Jan 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Apr 1, 2016 |
| First posted | Nov 30, 2006 |
| Last update posted | Jan 11, 2017 |
| Countries | Australia, Austria, Belarus, Belgium, Czechia, Denmark, France, Georgia, Germany, Greece, Ireland, Israel and 10 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: